Literature DB >> 33148623

Multimodal imaging of bacterial-host interface in mice and piglets with Staphylococcus aureus endocarditis.

Peter Panizzi1, Marvin Krohn-Grimberghe2,3, Edmund Keliher2, Yu-Xiang Ye2, Jana Grune2, Vanessa Frodermann2, Yuan Sun2, Charlotte G Muse1, Kaitlyn Bushey4, Yoshiko Iwamoto2, Mandy M T van Leent5, Anu Meerwaldt5, Yohana C Toner5, Jazz Munitz5, Alexander Maier5, Georgios Soultanidis5, Claudia Calcagno5, Carlos Pérez-Medina5,6, Giuseppe Carlucci7, Kay P Riddell8, Sharron Barney9, Glenn Horne9, Brian Anderson10, Ashoka Maddur-Appajaiah11, Ingrid M Verhamme11, Paul E Bock11, Gregory R Wojtkiewicz2, Gabriel Courties2, Filip K Swirski2, William R Church4, Paul H Walz8, D Michael Tillson9, Willem J M Mulder5,12,13, Matthias Nahrendorf14,15,16.   

Abstract

Acute bacterial endocarditis is a rapid, difficult to manage, and frequently lethal disease. Potent antibiotics often cannot efficiently kill Staphylococcus aureus that colonizes the heart's valves. S. aureus relies on virulence factors to evade therapeutics and the host's immune response, usurping the host's clotting system by activating circulating prothrombin with staphylocoagulase and von Willebrand factor-binding protein. An insoluble fibrin barrier then forms around the bacterial colony, shielding the pathogen from immune cell clearance. Targeting virulence factors may provide previously unidentified avenues to better diagnose and treat endocarditis. To tap into this unused therapeutic opportunity, we codeveloped therapeutics and multimodal molecular imaging to probe the host-pathogen interface. We introduced and validated a family of small-molecule optical and positron emission tomography (PET) reporters targeting active thrombin in the fibrin-rich environment of bacterial colonies. The imaging agents, based on the clinical thrombin inhibitor dabigatran, are bound to heart valve vegetations in mice. Using optical imaging, we monitored therapy with antibodies neutralizing staphylocoagulase and von Willebrand factor-binding protein in mice with S. aureus endocarditis. This treatment deactivated bacterial defenses against innate immune cells, decreased in vivo imaging signal, and improved survival. Aortic or tricuspid S. aureus endocarditis in piglets was also successfully imaged with clinical PET/magnetic resonance imaging. Our data map a route toward adjuvant immunotherapy for endocarditis and provide efficient tools to monitor this drug class for infectious diseases.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2020        PMID: 33148623      PMCID: PMC7818516          DOI: 10.1126/scitranslmed.aay2104

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  29 in total

1.  Hybrid PET-optical imaging using targeted probes.

Authors:  Matthias Nahrendorf; Edmund Keliher; Brett Marinelli; Peter Waterman; Paolo Fumene Feruglio; Lioubov Fexon; Misha Pivovarov; Filip K Swirski; Mikael J Pittet; Claudio Vinegoni; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

Review 2.  Endocarditis and molecular imaging.

Authors:  Peter Panizzi; James R Stone; Matthias Nahrendorf
Journal:  J Nucl Cardiol       Date:  2014-05-06       Impact factor: 5.952

Review 3.  Challenges in Infective Endocarditis.

Authors:  Thomas J Cahill; Larry M Baddour; Gilbert Habib; Bruno Hoen; Erwan Salaun; Gosta B Pettersson; Hans Joachim Schäfers; Bernard D Prendergast
Journal:  J Am Coll Cardiol       Date:  2017-01-24       Impact factor: 24.094

Review 4.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

5.  Fibrinogen substrate recognition by staphylocoagulase.(pro)thrombin complexes.

Authors:  Peter Panizzi; Rainer Friedrich; Pablo Fuentes-Prior; Klaus Richter; Paul E Bock; Wolfram Bode
Journal:  J Biol Chem       Date:  2005-10-17       Impact factor: 5.157

6.  Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion.

Authors:  G Köhler; C Milstein
Journal:  Eur J Immunol       Date:  1976-07       Impact factor: 5.532

7.  Genetic tools to enhance the study of gene function and regulation in Staphylococcus aureus.

Authors:  Jeffrey L Bose; Paul D Fey; Kenneth W Bayles
Journal:  Appl Environ Microbiol       Date:  2013-01-25       Impact factor: 4.792

Review 8.  Where does a Staphylococcus aureus vaccine stand?

Authors:  V G Fowler; R A Proctor
Journal:  Clin Microbiol Infect       Date:  2014-05       Impact factor: 8.067

9.  Noninvasive imaging of Staphylococcus aureus infections with a nuclease-activated probe.

Authors:  Frank J Hernandez; Lingyan Huang; Michael E Olson; Kristy M Powers; Luiza I Hernandez; David K Meyerholz; Daniel R Thedens; Mark A Behlke; Alexander R Horswill; James O McNamara
Journal:  Nat Med       Date:  2014-02-02       Impact factor: 53.440

10.  Complete genome of Staphylococcus aureus Tager 104 provides evidence of its relation to modern systemic hospital-acquired strains.

Authors:  Richard W Davis; Andrew D Brannen; Mohammad J Hossain; Scott Monsma; Paul E Bock; Matthias Nahrendorf; David Mead; Michael Lodes; Mark R Liles; Peter Panizzi
Journal:  BMC Genomics       Date:  2016-03-03       Impact factor: 3.969

View more
  2 in total

Review 1.  Native valve, prosthetic valve, and cardiac device-related infective endocarditis: A review and update on current innovative diagnostic and therapeutic strategies.

Authors:  Joop J P Kouijzer; Daniëlle J Noordermeer; Wouter J van Leeuwen; Nelianne J Verkaik; Kirby R Lattwein
Journal:  Front Cell Dev Biol       Date:  2022-10-03

Review 2.  Staphylococcus aureus and Neutrophil Extracellular Traps: The Master Manipulator Meets Its Match in Immunothrombosis.

Authors:  Severien Meyers; Marilena Crescente; Peter Verhamme; Kimberly Martinod
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-02-03       Impact factor: 8.311

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.